The Australian government has listed yet another drug to cure hepatitis C on the Pharmaceutical Benefits Scheme (PBS). The drug Epclusa® - a combination of sofosbuvir 400mg and velpatasvir 100mg - is the first of the direct-acting antiviral treatments effective for all types of the disease.
